StockDriftsStockDriftsBL Pharmtech (065170) has 7 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩550M ($382K) in reported transaction value. The earliest filing StockDrifts holds for BL Pharmtech is dated 2024-03-28; the most recent is 2026-01-20. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +684.93%, measured from each filing date to the latest available close.
| Date | Type | Source | Insider | Position | Shares | Price at filing | Return | Value |
|---|---|---|---|---|---|---|---|---|
| 2026-01-20 | BUY | Market Buy | 박영철 Youngcheol Park | CEO | 14.0K | ₩579 | +704.8% | ₩8M ($6K) |
| 2026-01-15 | BUY | Market Buy | 박영철 Youngcheol Park | CEO | 15.0K | ₩635 | +633.9% | ₩10M ($7K) |
| 2026-01-14 | BUY | Market Buy | 박영철 Youngcheol Park | CEO | 50.0K | ₩489 | +853.0% | ₩24M ($17K) |
| 2026-01-13 | BUY | Market Buy | 박영철 Youngcheol Park | CEO | 20.7K | ₩532 | +775.9% | ₩11M ($8K) |
| 2026-01-12 | BUY | Market Buy | 박영철 Youngcheol Park | CEO | 60.1K | ₩512 | +810.2% | ₩31M ($21K) |
| 2025-02-27 | BUY | 무상신주취득 | 송상근 Song Sang-geun | thanks | 40.0K | ₩1,878 | +148.1% | ₩75M ($52K) |
| 2025-02-27 | BUY | 무상신주취득 | 신동진 Shin Dong-jin | Internal director | 217.7K | ₩1,878 | +148.1% | ₩409M ($284K) |
| 2025-02-27 | BUY | 무상신주취득 | 박영철 Youngcheol Park | CEO | 4.5M | ₩1,878 | +148.1% | ₩8.5B ($5.9M) |
| 2024-12-15 | SELL | 자본감소 | 박영철 Youngcheol Park | CEO | -20.3M | ₩766 | -508.4% | ₩15.5B ($10.8M) |
| 2024-12-15 | SELL | 자본감소 | 신동진 Shin Dong-jin | Internal director | -979.8K | ₩766 | -508.4% | ₩751M ($521K) |
| 2024-12-15 | SELL | 자본감소 | 송상근 Song Sang-geun | thanks | -180.2K | ₩766 | -508.4% | ₩138M ($96K) |
| 2024-12-13 | BUY | Market Buy | 박영철 Youngcheol Park | CEO | 477.5K | ₩766 | +508.4% | ₩366M ($254K) |
| 2024-12-12 | BUY | Market Buy | 박영철 Youngcheol Park | CEO | 131.2K | ₩766 | +508.4% | ₩101M ($70K) |
| 2024-03-28 | BUY | 신규선임 | 송상근 Song Sang-geun | thanks | 200.2K | ₩1,579 | +195.1% | ₩316M ($220K) |
| 2024-03-28 | BUY | 신규선임 | 박영철 Youngcheol Park | CEO | 21.9M | ₩1,579 | +195.1% | ₩34.6B ($24.0M) |
| 2024-03-28 | BUY | 신규선임 | 신동진 Shin Dong-jin | Internal director | 1.1M | ₩1,579 | +195.1% | ₩1.7B ($1.2M) |
| 2024-03-28 | SELL | 장외매도 | 모아라이프플러스 Moa Life Plus | - | -21.7M | ₩1,579 | -195.1% | ₩34.3B ($23.8M) |
Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for BL Pharmtech. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.